The news: Eli Lilly’s obesity pill Foundayo won FDA approval this week, setting up the first oral weight loss drug battle with Novo Nordisk, whose Wegovy pill launched in early January.

Why it matters: Lilly and Novo control the FDA-approved injectable obesity drug market, with Lilly holding a clear lead.

• Novo’s Wegovy injection was first to market in 2021, followed by Lilly’s Zepbound in 2023.
• Zepbound’s superior efficacy has made it the preferred choice among doctors, propelling it past Wegovy to roughly 60% market share.
• Zepbound sales increased by 123% year over year in Q4 2025, while Wegovy’s sales grew by just 17%.

But Novo has the early edge in pills, thanks to its three-month head start and stronger effectiveness claims.

• More than 600,000 prescriptions for Wegovy pill have been written so far this year.
• Novo released a comparative study on Wednesday, noting a 3.2 percentage point weight loss advantage over orforglipron (Foundayo’s generic name) and lower discontinuation rates due to adverse events.
• For its part, Lilly is touting Foundayo’s flexibility compared with Novo’s Wegovy pill. Foundayo can be taken any time of day, with or without food or water, compared with Wegovy pill, which must be taken in the morning, with a 30-minute wait before eating or drinking.

Implications for obesity drug marketers: Both Lilly and Novo are aiming to expand the GLP-1 weight loss drug market with more accessible, convenient pill options that could broaden uptake.

Consumers are already familiar with both brands, and will increasingly request their drug products by name, making brand recognition and loyalty more important than is typical in pharma. That shift will likely increase emphasis and spending on direct-to-consumer marketing.

Lilly and Novo’s marketing challenges also signal what’s ahead as additional players—including AstraZeneca, Pfizer, Roche, and Structure Therapeutics—look to bring their own obesity pills to market. Their early positioning around convenience and efficacy could shape how other brands try to differentiate in the future crowded field.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.